Czechia

Key Insights

1
No psychedelic therapy is yet broadly approved for routine patient care in Czechia; ketamine is used medically, while psilocybin remains in research or tightly controlled programmes. ([sukl.gov.cz](https://sukl.gov.cz/en/pharmaceutical-industry/cannabis-for-medicinal-purposes/pharmacists/regulation/?utm_source=openai))
2
Czechia logs 16 trials, 5 active, with psilocybin and LSD leading activity; active studies also include ketamine and placebo. ([nudz.cz](https://www.nudz.cz/en/research/psychedelic-research-center?utm_source=openai))
3
Prague ran one of the world’s largest LSD clinical programmes in the 1950s-60s, with over 700 patients and volunteers across more than 6,000 sessions. ([en.wikipedia.org](https://en.wikipedia.org/wiki/LSD_in_Czechoslovakia?utm_source=openai))
4
Momentum centres on the National Institute of Mental Health and EU-funded work such as PsyPal, plus a 1 January 2025 regulatory reset that is sharpening the research runway. ([nudz.cz](https://www.nudz.cz/en/news-and-events/first-patient-included-marks-major-milestone-in-eu-funded-clinical-trial?utm_source=openai))

Medical Only (Private)

Reimbursed Care Access

As of early 2026 Czechia permits tightly regulated medical use of psilocybin and has registered esketamine (Spravato); ketamine is widely used off‑label in psychiatry (mostly outside full public reimbursement). Other classical psychedelics (MDMA, DMT and derivatives, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) remain scheduled/controlled and are only available within authorised research or otherwise prohibited contexts under the narcotics law framework.

Full guide →